$CRSP News

Learn Why The Bull Case For CRISPR Therapeutics Stock Could Change Following CFO Change

CRISPR Therapeutics (CRSP) Promotes Andrew Silver To CFO As Raju Prasad Resigns

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know

The Outlook of CRISPR Therapeutics Stock Does Not Look Strong After Its CFO Resigns

CRISPR Therapeutics AG (CRSP) Stock Moves -1.21%: What You Should Know

Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet

CRISPR Therapeutics Announces Chief Financial Officer Transition

CRISPR Therapeutics Appoints A. J. Silver CFO, Effective Immediately, Succeeding Raju Prasad

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know

UBS Initiates Coverage On CRISPR Therapeutics with Neutral Rating, Announces Price Target of $52

Is CRISPR Therapeutics (CRSP) Undervalued As CASGEVY Hopes Face Market Doubts?

CRISPR Therapeutics (CRSP) Stock Looks Rich On Upcoming CTX310 Trial Data

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know

Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026

CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade

Wall Street Bulls Look Optimistic About CRISPR Therapeutics (CRSP): Should You Buy?

CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026

Anthropic Just Made a CRISPR-Like Discovery. What It Actually Means for CRSP Stock Investors.

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know